MDMA, the psychoactive drug sometimes known as ecstasy, is poised to become a powerful tool in the treatment of PTSD. In 2017, the U.S. Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy. Although MDMA itself is not...

Luminaries in addiction research, policy, and clinical care, led by keynote speaker Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA), participated in an all-day conference in the fall hosted by the Addiction Institute of...

Yasmin Hurd, PhD, Director of the Addiction Institute of Mount Sinai (AIMS), has been at the forefront of cannabidiol (CBD) research for the past decade, particularly its effects on those struggling with addiction. In May 2019, she published study results from a...

In November, Mount Sinai’s Center of Excellence in Eating and Weight Disorders launched its new Intensive Program in an integrated clinical and research space at 53 East 96th Street. What began in 2002 as the Division of Eating and Weight Disorders has since grown...

The 2019 NARSAD Young Investigator grantees from the Brain and Behavior Research Foundation include six faculty members from the Icahn School of Medicine at Mount Sinai. Their research aims are listed below. Jessica Ables, MD, PhD, seeks to determine the effect of...

Mount Sinai’s Partial Hospital Program provides an intensive level of psychiatric care for patients with acute symptoms—without hospitalization. The program treats patients with a range of psychiatric conditions, and places them on specialized tracks based on symptom...